ATYR aTYR PHARMA INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$0.49

Period return

-0.26 (-34.87%)

Volume

861.6K

2026-07-21O $0.49 H $0.51 L $0.48 C $0.49MA5 $0.51MA20 $0.55MA60 $0.58MA120 $0.73

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 21.MediumBUY2 months ago
Freedom Broker: Buy
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2025. 11. 08.Low9 months ago
RBC Capital: r Perform
US analyst rating / recommendation change.
2025. 09. 16.MediumHOLD10 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2025. 09. 16.MediumHOLD10 months ago
RBC Capital: Sector Perform
US analyst rating / recommendation change.
2025. 09. 16.MediumHOLD10 months ago
HC Wainwright & Co.: Neutral
US analyst rating / recommendation change.
2025. 09. 15.MediumHOLD10 months ago
Leerink Partners: Market Perform
US analyst rating / recommendation change.
2025. 09. 15.MediumHOLD10 months ago
Jones Trading: Hold
US analyst rating / recommendation change.
2025. 09. 15.MediumHOLD10 months ago
Cantor Fitzgerald: Neutral
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $2.86 · 7 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
HQ: San Diego, CA, United States
Fiscal year end: —
Employees: 58

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$-0.12	—	—	$0	—	Scheduled
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.69	—	—	$235K	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.46	—	—	$235K	Reported
FY2025 Q1	2024. 03. 31.	Time TBD	—	$-0.23	—	—	$235K	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,144,565	$892.76K	0.00%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	454,443	$355.87K	0.00%	—	New position

aTYR PHARMA INC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 21.	Freedom Broker	—	Upgrade	Hold → Buy	—	Freedom Broker: Hold → Buy
2025. 11. 08.	RBC Capital	—	Maintain	Sector Perform → Sector Perform	—	RBC Capital: Sector Perform
2025. 09. 16.	Wells Fargo	—	Downgrade	Overweight → Equal-Weight	—	Wells Fargo: Overweight → Equal-Weight
2025. 09. 16.	RBC Capital	—	Downgrade	Outperform → Sector Perform	—	RBC Capital: Outperform → Sector Perform
2025. 09. 16.	HC Wainwright & Co.	—	Downgrade	Buy → Neutral	—	HC Wainwright & Co.: Buy → Neutral
2025. 09. 15.	Leerink Partners	—	Downgrade	Outperform → Market Perform	—	Leerink Partners: Outperform → Market Perform